So we're here today to talk about the launch of our new product, Ilumira. I'm really excited to be talking about it with you guys, and really excited about what it can do for cancer patients and for the world. First and foremost, it's our first real product launch in the Medical Isotopes arena. After many, many years of development, the logo itself and the name, it's very clever in a number of dimensions.
First, starting out with Ilum, it follows a team of illumination. The parent company of our company SHINE is Illuminated holdings and following the theme of light illuminating and finding disease, as new theronostic techniques developed. It's got lu in it. Lu the chemical symbol for lutetium, which is fundamentally what the product is. Then, as you look at the word mir in romance languages, means wonderful or wondrous treating cancer, especially people who historically have had no hope.
It's just really wondrous thing to be able to do. We're at the tip of the iceberg with what these medicines can do. And then there's a little, little bonus at the end of the ra. Just kind of reminds me of the the sun god Ra. A lot of things come together. A lot of cool elements to it. But fundamentally the most exciting thing is that it's our first branded medical isotope product.
After many, many years of development. We chose to focus on commercializing Lutetium because it's an important isotope from a cancer therapy perspective. Both has the capability of illuminating disease and treating disease all within the same isotope. The other reason that we were drawn to it, though, is the supply chain is particularly challenged. It's a really difficult isotope to make.
You need to be able to make raw material enriched form of ytterbium-176 you need to be able to make neutrons at significant quantities, and then you need to be able to do really advanced radio chemical processing. And these are all areas we excel. And our company is very special on that. We can bring expertise and capability across all three of these dimensions.
In fact, over time, we'll plan to use our own Chrysalis facility as the source of neutrons. So we really determined that our capabilities were almost essential for solving the lutetium-177 supply chain problems. We were able to move very, very quickly. So now we're really thrilled that our Cassiopeia, our large-scale facility is online for initial product deliveries to customers have been really well received.
Product quality is great, people are very happy with it and so we look forward to scaling with our customers as their demand grows. We've got a lot of capacity there and are really excited to have brought this capability to North America. And we're partnering with drug developers who are bringing new therapies to market. As we get more advanced and we do treatment planning and more sophisticated dose imagery, that's going to improve clinical outcomes, I believe, significantly over where we are.
And then we're still just at the beginning in terms of what isotopes we can use. We see ourselves as one of the innovators in this space. We're going to help bring about the revolution that's just beginning in cancer therapy.
.png)
